Abstract
The neuronal nicotinic alpha7-acetylcholine receptor (α7-nAChR) is a promising and attractive drug target for improving cognitive deficits in neuropsychiatric and neurological disorders such as Alzheimer's disease (AD). α7-nAChR belongs to the family of ligand gated ion channels. α7-nAChR is expressed in key brain regions (e.g. pre- and frontal cortex, hippocampus). It is involved in essential cognitive functions such as memory, thinking, comprehension, learning capacity, calculation, orientation, language, and judgment. α7-nAChR binds to amyloid peptide (Aβ) inducing either receptor activation or inhibition in an Aβ concentration-dependent mode. Aβ oligomers induce Τ phosphorylation via α7-nAChR activation. α7-nAChR agonists and/or α7-nAChR positive allosteric modulators may be useful in AD therapy. The current review enlightens: (i) α7-nAChR neurobiology, (ii) α7-nAChR role in cognition and (iii) in AD, and (iv) the clinical status of the most promising molecules for the treatment of cognitive dysfunction in AD.
Keywords: alpha7-nAChR neurobiology, alpha7-nAChR role in cognition, Alzheimer's disease, new drugs.
Current Pharmaceutical Design
Title:Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials
Volume: 20 Issue: 38
Author(s): Patrizia Russo, Alessandra Del Bufalo, Alessandra Frustaci, Massimo Fini and Alfredo Cesario
Affiliation:
Keywords: alpha7-nAChR neurobiology, alpha7-nAChR role in cognition, Alzheimer's disease, new drugs.
Abstract: The neuronal nicotinic alpha7-acetylcholine receptor (α7-nAChR) is a promising and attractive drug target for improving cognitive deficits in neuropsychiatric and neurological disorders such as Alzheimer's disease (AD). α7-nAChR belongs to the family of ligand gated ion channels. α7-nAChR is expressed in key brain regions (e.g. pre- and frontal cortex, hippocampus). It is involved in essential cognitive functions such as memory, thinking, comprehension, learning capacity, calculation, orientation, language, and judgment. α7-nAChR binds to amyloid peptide (Aβ) inducing either receptor activation or inhibition in an Aβ concentration-dependent mode. Aβ oligomers induce Τ phosphorylation via α7-nAChR activation. α7-nAChR agonists and/or α7-nAChR positive allosteric modulators may be useful in AD therapy. The current review enlightens: (i) α7-nAChR neurobiology, (ii) α7-nAChR role in cognition and (iii) in AD, and (iv) the clinical status of the most promising molecules for the treatment of cognitive dysfunction in AD.
Export Options
About this article
Cite this article as:
Russo Patrizia, Bufalo Del Alessandra, Frustaci Alessandra, Fini Massimo and Cesario Alfredo, Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140316130720
DOI https://dx.doi.org/10.2174/1381612820666140316130720 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Flavonoids as Promising Therapeutics of the Future: A Hub for Cells Survival or Death
Current Medicinal Chemistry Nanoparticles-mediated Brain Imaging and Disease Prognosis by Conventional as well as Modern Modal Imaging Techniques: a Comparison
Current Pharmaceutical Design The Use of <i>Cannabis</i> and Cannabinoid-based Products by Pregnant Women: A Patent Review
Recent Patents on Biotechnology Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research A System Pharmacology Study for Deciphering Anti Depression Activity of Nardostachys jatamansi
Current Drug Metabolism 1,3,4-Thiadiazole: A Versatile Pharmacophore of Medicinal Significance
Medicinal Chemistry PDZ Domain-mediated Protein Interactions: Therapeutic Targets in Neurological Disorders
Current Medicinal Chemistry Editorial
Current Medical Imaging Psychomotor Seizure Test, Neurotoxicity and in vitro Neuroprotection Assay of some Semicarbazone Analogues
Central Nervous System Agents in Medicinal Chemistry Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds Editorial [Hot Topic: Monotherapy to Polytherapy: Antiepileptic Drug Conversions Through the Spectrum of Epilepsy Care (Guest Editor: Erik K. St. Louis)]
Current Neuropharmacology Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery A Review Focused on Molecular Mechanisms of Anxiolytic Effect of <i>Valerina officinalis</i> L. in Connection with Its Phytochemistry through <i>in vitro/in vivo</i> Studies
Current Pharmaceutical Design Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Combined Virtual Screening Strategies
Current Computer-Aided Drug Design Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Various Effects of the GABAergic System on Cancer: The Conditions and Specificities of its use in the Treatment of Some Cancers
Current Topics in Medicinal Chemistry